Literature DB >> 24518035

2-isoxazol-3-phenyltropane derivatives of cocaine: molecular and atypical system effects at the dopamine transporter.

Takato Hiranita1, Derek S Wilkinson, Weimin C Hong, Mu-Fa Zou, Theresa A Kopajtic, Paul L Soto, Carl R Lupica, Amy H Newman, Jonathan L Katz.   

Abstract

The present study examined RTI-371 [3β-(4-methylphenyl)-2β-[3-(4-chlorophenyl)-isoxazol-5-yl]tropane], a phenyltropane cocaine analog with effects distinct from cocaine, and assessed potential mechanisms for those effects by comparison with its constitutional isomer, RTI-336 [3β-(4-chlorophenyl)-2β-[3-(4-methylphenyl)-isoxazol-5-yl]tropane]. In mice, RTI-371 was less effective than cocaine and RTI-336 in stimulating locomotion, and incompletely substituted (∼60% maximum at 5 minutes or 1 hour after injection) in a cocaine (10 mg/kg i.p.)/saline discrimination procedure; RTI-336 completely substituted. In contrast to RTI-336, RTI-371 was not self-administered, and its pretreatment (1.0-10 mg/kg i.p.) dose-dependently decreased maximal cocaine self-administration more potently than food-maintained responding. RTI-336 pretreatment dose-dependently left-shifted the cocaine self-administration dose-effect curve. Both RTI-336 and RTI-371 displaced [(3)H]WIN35,428 [[(3)H](-)-3β-(4-fluorophenyl)-tropan-2β-carboxylic acid methyl ester tartrate] binding to striatal dopamine transporters (DATs) with Ki values of 10.8 and 7.81 nM, respectively, and had lower affinities at serotonin or norepinephrine transporters, or muscarinic and σ receptors. The relative low affinity at these sites suggests the DAT as the primary target of RTI-371 with minimal contributions from these other targets. In biochemical assays probing the outward-facing DAT conformation, both RTI-371 and RTI-336 had effects similar to cocaine, suggesting little contribution of DAT conformation to the unique pharmacology of RTI-371. The locomotor-stimulant effects of RTI-371 (3.0-30 mg/kg i.p.) were comparable in wild-type and knockout cannabinoid CB1 receptor (CB1R) mice, indicating that previously reported CB1 allosteric effects do not decrease cocaine-like effects of RTI-371. DAT occupancy in vivo was most rapid with cocaine and least with RTI-371. The slow apparent association rate may allow compensatory actions that in turn dampen cocaine-like stimulation, and give RTI-371 its unique pharmacologic profile.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24518035      PMCID: PMC3989806          DOI: 10.1124/jpet.113.212738

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  44 in total

1.  Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands.

Authors:  Jonathan L Katz; Theresa A Kopajtic; Gregory E Agoston; Amy Hauck Newman
Journal:  J Pharmacol Exp Ther       Date:  2004-01-30       Impact factor: 4.030

2.  Comparison of binding parameters of sigma 1 and sigma 2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes.

Authors:  V H Nguyen; M Kassiou; G A Johnston; M J Christie
Journal:  Eur J Pharmacol       Date:  1996-09-12       Impact factor: 4.432

3.  Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and σ receptors.

Authors:  Takato Hiranita; Paul L Soto; Stephen J Kohut; Theresa Kopajtic; Jianjing Cao; Amy H Newman; Gianluigi Tanda; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2011-08-22       Impact factor: 4.030

4.  Relationships among dopamine transporter affinities and cocaine-like discriminative-stimulus effects.

Authors:  J L Katz; S Izenwasser; P Terry
Journal:  Psychopharmacology (Berl)       Date:  2000-01       Impact factor: 4.530

5.  N-substituted benztropine analogs: selective dopamine transporter ligands with a fast onset of action and minimal cocaine-like behavioral effects.

Authors:  Su-Min Li; Theresa A Kopajtic; Matthew J O'Callaghan; Gregory E Agoston; Jianjing Cao; Amy Hauck Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2010-11-18       Impact factor: 4.030

Review 6.  Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse.

Authors:  F Ivy Carroll; James L Howard; Leonard L Howell; Barbara S Fox; Michael J Kuhar
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

7.  Stimulant actions of histamine H1 antagonists on operant behavior in the squirrel monkey.

Authors:  J W McKearney
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

8.  Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change.

Authors:  Gianluigi Tanda; Su Min Li; Maddalena Mereu; Alexandra M Thomas; Aaron L Ebbs; Lauren E Chun; Valeria Tronci; Jennifer L Green; Mu-Fa Zou; Theresa A Kopajtic; Amy Hauck Newman; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2013-04-24       Impact factor: 4.530

9.  Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors.

Authors:  Takato Hiranita; Paul L Soto; Amy H Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2009-02-19       Impact factor: 4.030

10.  Synthesis, monoamine transporter binding properties, and behavioral pharmacology of a series of 3beta-(substituted phenyl)-2beta-(3'-substituted isoxazol-5-yl)tropanes.

Authors:  F Ivy Carroll; Neil Pawlush; Michael J Kuhar; Gerald T Pollard; James L Howard
Journal:  J Med Chem       Date:  2004-01-15       Impact factor: 7.446

View more
  16 in total

1.  σ Receptor Effects of N-Substituted Benztropine Analogs: Implications for Antagonism of Cocaine Self-Administration.

Authors:  Takato Hiranita; Weimin C Hong; Theresa Kopajtic; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2017-04-25       Impact factor: 4.030

2.  Dopamine Transporter Dynamics of N-Substituted Benztropine Analogs with Atypical Behavioral Effects.

Authors:  Weimin C Hong; Michael J Wasko; Derek S Wilkinson; Takato Hiranita; Libin Li; Shuichiro Hayashi; David B Snell; Jeffry D Madura; Christopher K Surratt; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2018-06-26       Impact factor: 4.030

3.  Cocaine Antagonists; Studies on Cocaine Self-Administration.

Authors:  Takato Hiranita
Journal:  J Alcohol Drug Depend       Date:  2015-09-03

4.  Identification of Antagonists Selective for Sigma Receptor Subtypes that are Active In vivo.

Authors:  Takato Hiranita
Journal:  J Alcohol Drug Depend       Date:  2016-07-11

5.  DAT Conformation Does Not Predict the Ability of Atypical Dopamine Uptake Inhibitors to Substitute for Cocaine.

Authors:  Takato Hiranita
Journal:  J Alcohol Drug Depend       Date:  2016-08-08

6.  Identification of a Novel Allosteric Modulator of the Human Dopamine Transporter.

Authors:  Shaili Aggarwal; Xiaonan Liu; Caitlyn Rice; Paul Menell; Philip J Clark; Nicholas Paparoidamis; You-Cai Xiao; Joseph M Salvino; Andréia C K Fontana; Rodrigo A España; Sandhya Kortagere; Ole V Mortensen
Journal:  ACS Chem Neurosci       Date:  2019-06-24       Impact factor: 4.418

7.  Structure-Activity Relationship Studies on a Series of 3α-[Bis(4-fluorophenyl)methoxy]tropanes and 3α-[Bis(4-fluorophenyl)methylamino]tropanes As Novel Atypical Dopamine Transporter (DAT) Inhibitors for the Treatment of Cocaine Use Disorders.

Authors:  Mu-Fa Zou; Jianjing Cao; Ara M Abramyan; Theresa Kopajtic; Claudio Zanettini; Daryl A Guthrie; Rana Rais; Barbara S Slusher; Lei Shi; Claus J Loland; Amy Hauck Newman
Journal:  J Med Chem       Date:  2017-12-11       Impact factor: 7.446

Review 8.  Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter.

Authors:  Maarten E A Reith; Bruce E Blough; Weimin C Hong; Kymry T Jones; Kyle C Schmitt; Michael H Baumann; John S Partilla; Richard B Rothman; Jonathan L Katz
Journal:  Drug Alcohol Depend       Date:  2014-12-18       Impact factor: 4.492

9.  Novel and High Affinity 2-[(Diphenylmethyl)sulfinyl]acetamide (Modafinil) Analogues as Atypical Dopamine Transporter Inhibitors.

Authors:  Jianjing Cao; Rachel D Slack; Oluyomi M Bakare; Caitlin Burzynski; Rana Rais; Barbara S Slusher; Theresa Kopajtic; Alessandro Bonifazi; Michael P Ellenberger; Hideaki Yano; Yi He; Guo-Hua Bi; Zheng-Xiong Xi; Claus J Loland; Amy Hauck Newman
Journal:  J Med Chem       Date:  2016-11-28       Impact factor: 7.446

10.  2-Substituted 3β-Aryltropane Cocaine Analogs Produce Atypical Effects without Inducing Inward-Facing Dopamine Transporter Conformations.

Authors:  Weimin C Hong; Theresa A Kopajtic; Lifen Xu; Stacey A Lomenzo; Bernandie Jean; Jeffry D Madura; Christopher K Surratt; Mark L Trudell; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2016-01-14       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.